Short answer
Humacyte, Inc. (HUMA) filed an 8-K current report with the SEC on March 19, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Preliminary financial results for year ended December 31, 2025 disclosed under "Operational Updates".
Humacyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary financial results for year ended December 31, 2025 disclosed under "Operational Updates"
- Indicates upcoming or recent update on company's operational and financial performance for 2025
Item 8.01 · Other Events
- Suspension of $60M ATM equity offering prospectus limits near-term capital raise options using sales agreement with TD Cowen
- Preliminary 2025 financials: $50.9M cash, $2.0M revenue incl. $1.4M product sales, 61 Symvess units sold, pending final audit
- $1.48M confirmed Symvess vessel purchase committed in Saudi Arabia, with exclusive JV negotiation rights through July 2026
- Marketing Authorization Application filed for Symvess vascular trauma use in Israel; early hospital access efforts underway
- Updated risk factors disclosed highlight ongoing regulatory, commercial, and operational uncertainties surrounding Symvess commercialization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Humacyte, Inc. 8-K filings
Get the next HUMA 8-K as it lands
Follow HUMA for push alerts, or ask the research agent what this filing means.